USFDA puts plans to test LSD in anxiety patients in clinical study on hold

Mind Medicine Inc, a drug known as LSD in psychedelic patients with generalized anxiety disorder, has put a clinical hold on Mind Medicine Inc’s request to start testing the drug.

The allyrgic acid diethylamide, a lysergic acid, is the lead-to-step trial of the drug, according to the pharmaceutical and drug manufacturer.

Mind Medicine predicted that more detailed information on the FDA’s decision should be obtained within 30 days.

The FDA’s move is the latest blow to the psychedelic industry’s efforts to utilize LSD and other compounds such as psilocybin for therapeutic purposes.

Mind Medicine’s share rated at $1.46 before the bell, falling 10.4%.

Compass Pathways shares have declined approximately 16 percent in November due to safety concerns on COMP360, a experimental drug that uses the psycho-active compound in’magic’ mushrooms to treat depression. List23